Drawing on case law and the results of an empirical study, this paper demonstrates that the height of the inventive step in Australia is close to zero and substantially different from the "significant advance over what is known" advised to the Australian parliament in 2011. To "raise" the height...

Litigated pharmaceutical patents are a valuable source of data on how much inventiveness is required for a patent grant and what are the costs of patents. Although innovation is central to economic growth and the competitiveness of firms, there are few data about either the cost of granted...